Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

Exclusion Criteria

• •Presence of any intracranial hemorrhage (ICH) on head computed tomography (CT) or non-petechial ICH on screening MRI.
• •Stroke isolated to the brainstem.
• •Presence of coma
• •Expected to die OR unable to be evaluated within 5 days.
• •Hypotension requiring the use of intravenous (IV) vasopressor support or systolic blood pressure \<90 mmHg at the time of randomization.
• •Known prior treatment with natalizumab.
• •Immunocompromised subjects, as determined by the Investigator.
• •History of progressive multifocal leukoencephalopathy (PML).
• •Contraindications to MRI, e.g., implanted pacemaker or other contraindicated implanted metal devices, history of or risk for side effects from gadolinium, or claustrophobia that cannot be medically managed.